- Home
- JL vs CERO Comparison
JL vs CERO Comparison
Compare JL & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- CERO
- Stock Information
- Founded
- JL 1985
- CERO 2017
- Country
- JL Hong Kong
- CERO United States
- Employees
- JL N/A
- CERO N/A
- Industry
- JL
- CERO
- Sector
- JL
- CERO
- Exchange
- JL NYSE
- CERO Nasdaq
- Market Cap
- JL 13.7M
- CERO 12.2M
- IPO Year
- JL 2024
- CERO N/A
- Fundamental
- Price
- JL $0.37
- CERO $0.29
- Analyst Decision
- JL
- CERO
- Analyst Count
- JL 0
- CERO 0
- Target Price
- JL N/A
- CERO N/A
- AVG Volume (30 Days)
- JL 4.1M
- CERO 174.9M
- Earning Date
- JL 11-29-2024
- CERO 11-25-2024
- Dividend Yield
- JL N/A
- CERO N/A
- EPS Growth
- JL N/A
- CERO N/A
- EPS
- JL 0.03
- CERO N/A
- Revenue
- JL $28,378,669.00
- CERO N/A
- Revenue This Year
- JL N/A
- CERO N/A
- Revenue Next Year
- JL N/A
- CERO N/A
- P/E Ratio
- JL $14.29
- CERO N/A
- Revenue Growth
- JL N/A
- CERO N/A
- 52 Week Low
- JL $0.30
- CERO $0.06
- 52 Week High
- JL $29.95
- CERO $12.80
- Technical
- Relative Strength Index (RSI)
- JL 43.50
- CERO 73.26
- Support Level
- JL $0.38
- CERO $0.17
- Resistance Level
- JL $0.53
- CERO $0.33
- Average True Range (ATR)
- JL 0.13
- CERO 0.04
- MACD
- JL -0.02
- CERO 0.02
- Stochastic Oscillator
- JL 1.60
- CERO 57.68
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.